MISSISSIPPI DIVISION OF MEDICAID	PHARN Division of I Pharmacy F 550 High St	Medicaid Prior Author	ization U	nit		ORIZA	ΙΟΙΤ	N FO	RM	FAX TO: <b>1-877-537-0720</b> For Information Call: 1-877-537-0722
Beneficiary ID#:										
Beneficiary Full N	Name:									DOB:
Prescriber NPI:										
Prescriber's Full	Name:									Phone:
Prescriber's Add	ress:									FAX:
Pharmacy NPI:										
Pharmacy Name Phone:										FAX:
PA Start Date							-			Quantity
										Quantity
Hospital Disc	harge	Additic	onal Me	edical	Justifi	cation	Attach	ed		cceptable as justification.
Early Refill (I      Enteral Nutrit      Max Unit Ove      Medical Neces      Preferred Dru	Must includ ion (Mus rride (M ssity Prior / g List Exce Therapy (I ons)	de Early F st include ust incluc <u>Authoriza</u> ption Reg Months 1	Refill Pa Entera le Max <u>ation Fo</u> <u>uest</u> –2) or <u>s</u>	de Me ge 2 fi I Page Overr <u>orm fo</u> (Musi Solvalo	dWato rom in 2 fror ide Pa <u>r EPSD</u> t inclue <u>di Ong</u>	nstruction m instru ge 2 fro <u>DT-eligil</u> de Pref coing Th	e and B ons) uctions om inst <u>ble ber</u> erred l	rand N ;) ructio neficiar Drug Li	lame M ns) <u>ries</u> (Mu st Exce	Multi Source Page 2 from instructions) lust include Children's Page 2 from instructions) eption Page 2 from instructions) de Sovaldi Initial or Ongoing Therapy Page 2
Appeal/Recon	usideration AGE TWO	(Must	include	e Appe	eal/Red	conside				2 from Instructions) er than the provider, are not acceptable)
Signature requi	red:									Date:
Printed name o	-									
	MOUNT OF	PAYMENT	. ELIGI	BILITY	FOR AI					JARANTEE MEDICAID PAYMENT FOR PHARMACY ERVICES ARE SUBJECT TO ALL TERMS AND



Division of Medicaid

Pharmacy Prior Authorization Unit 550 High St., Suite 1000, Jackson, MS 39201 FAX TO: 1-877-537-0720

For Information Call: 1-877-537-0722

As of January 1, 2014 and in order for DOM to be in compliance with state law, submissions on forms used previously can no longer be accepted for Medicaid beneficiaries and will be returned to the prescriber.

## **PA Determination**

If the Pharmacy PA unit approves the prior authorization, the beneficiary can return to their pharmacy to obtain the prescription. The drug claim will pay and no further action will be required.

If the Pharmacy PA denies the request, the prescriber's office will be notified immediately. The prescriber has the option of prescribing a different treatment course that does not require prior authorization or submitting the required form.

**REMINDER:** Before submitting a PA request, check for options not requiring PA on the current PDL found at <u>http://www.medicaid.ms.gov/Pharmacy.aspx</u>. Medicaid providers are encouraged to use equally efficacious and cost saving **preferred** agents whenever possible.

## **NOTICE: Instructions for successfully completing a Prior Authorization Form**

**<u>Prior Authorization Page 1 along with ONE of the pages below</u> must be completed and faxed in for prior authorization.** 

## **Drug Specific Information:**

Brand Name Multi Source	Page 2.A
Early Refill	Page 2.B
Enteral Nutrition	Page 2.C
Max Unit Override	Page 2.D
Medical Necessity Prior Authorization Form for EPSDT-eligible beneficiaries	Page 2.E
Preferred Drug List Exception Request	Page 2.F
Solvaldi Initial Therapy (Months 1–2) or Solvaldi Ongoing Therapy	Page 2.G
<u>Synagis</u>	Page 2.H
Appeal/Reconsideration	D 01

SUBMISSION AND/OR APPROVAL OF A DRUG PRIOR AUTHORIZATION REQUEST DOES NOT GUARANTEE MEDICAID PAYMENT FOR PHARMACY PRODUCTS OR THE AMOUNT OF PAYMENT. ELIGIBILITY FOR AND PAYMENT OF MEDICAID SERVICES ARE SUBJECT TO ALL TERMS AND CONDITIONS AND LIMITATIONS OF THE MEDICAID PROGRAM.





Pharmacy Prior Authorization Unit 550 High St., Suite 1000, Jackson, MS 39201

\_ ....

For Information Call: 1-877-537-0722

Beneficiary ID#:

Beneficiary Full Name:

## Brand-Name Multi-Source Drug / Dispense As Written (DAW)\* Form 2A

PRIOR AUTHORIZATION REQUEST FORM

\*MS Division of Medicaid requires that all information requested on this form be completed for consideration of approval

#### The following brand name drugs are excluded from this requirement:

- DOM designated narrow therapeutic index drugs or NTI are Coumadin, Dilantin, Lanoxin, Synthroid, and Tegretol.
- Preferred branded drugs on DOM's PDL.

*The completed FDA MedWatch form must be included with this request.* A copy of the FDA MedWatch form may be obtained online *at:* <u>http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM163919.pdf</u>

## DOCUMENTATION OF TRIAL OF GENERIC PRODUCT

Generic Product:	_ Manufacturer:
Length of therapy	
Observed adverse reaction or allergic reaction:	
Generic Product:	_ Manufacturer:
Generic Product: Length of therapy	
Length of therapy	

Has a completed FDA MedWatch form been submitted to FDA: Yes No?

PAGE 2.A

SUBMISSION AND/OR APPROVAL OF A DRUG PRIOR AUTHORIZATION REQUEST DOES NOT GUARANTEE MEDICAID PAYMENT FOR PHARMACY PRODUCTS OR THE AMOUNT OF PAYMENT. ELIGIBILITY FOR AND PAYMENT OF MEDICAID SERVICES ARE SUBJECT TO ALL TERMS AND CONDITIONS AND LIMITATIONS OF THE MEDICAID PROGRAM.



MISSISSIPPI DIVISION OF
MEDICAID
-

Pharmacy Prior Authorization Unit 550 High St., Suite 1000, Jackson, MS 39201

For Information Call: 1-877-537-0722

**Beneficiary ID#:** 

Beneficiary Full Name: \_

## Early Refill Pharmacy Prior Authorization Form\* Form 2B

## MS Division of Medicaid requires that all information requested on this form be completed for consideration of approval.

- No early refill can be authorized if the beneficiary's monthly service limit has been reached.
- MS Medicaid does not generally reimburse for replacement of prescriptions that are lost, stolen or otherwise destroyed.
- MS Medicaid does not pay for vacation supplies.
- Current policy requires at least:
  - 75% of a non-controlled substance prescription claim's day's supply to transpire to pay or a PA request to be approved; or
  - 85 % of a controlled substance prescription claim's day's supply to transpire to pay or a PA request to be approved.

## Reason for Request:

Prescriber increased the dosing frequency
Prescriber increased the number of units per dose
New Admission to Nursing Home
Extra medication needed to stop or mitigate further morbidity due to acute clinical Condition.
Explanation:
Lost or Stolen: Documentation required**
Destroyed (fire, natural disaster, such as flood tornado, hurricane): Documentation required**
Other, <i>Specify</i> :

#### Additional Comments:

\*The pharmacist should maintain documentation for each early refill override that is obtained from **DOM**.

\*\* Documentation must be provided for prescriptions for controlled substances and/or medication with a potential for abuse or resale. Examples of documentation include a police report, insurance report, etc.

\*\*\*Supporting documentation must be available in the patient record

# PAGE 2.B

SUBMISSION AND/OR APPROVAL OF A DRUG PRIOR AUTHORIZATION REQUEST DOES NOT GUARANTEE MEDICAID PAYMENT FOR PHARMACY PRODUCTS OR THE AMOUNT OF PAYMENT. ELIGIBILITY FOR AND PAYMENT OF MEDICAID SERVICES ARE SUBJECT TO ALL TERMS AND CONDITIONS AND LIMITATIONS OF THE MEDICAID PROGRAM.

1	PHARMACY PRIOR AUTHORIZ	ATION FORM	<b>FAX TO: 1-877-537-0720</b> For Information Call	
MISSISSIPPI DIVISION OF	Pharmacy Prior Authorization Unit 550 High St., Suite 1000, Jackson, MS 39201		1-877-537-0722	
MEDICAID			1-8//-53/-0/22	-
Beneficiary ID#:	Be	eneficiary Full Name	ne:	
NON-PREFERRE	ED ENTERAL NUTRITION Pharmacy	Prior Authoriza	zation Form Form 2C	
<ul> <li>Enteral nu as nursing treatment</li> <li>Is the beneficion</li> <li>Is beneficion</li> <li>Is nutrition</li> <li>EPSDT elig for women</li> <li>If</li> <li>If</li> </ul>	home, Intermediate Care Facility for Indivi facility (PRTF)) and are not reimbursable se ficiary Medicare eligible? Medicare Part B must be billed if the benefici ary > 21 years of age? YES al requested the sole source of nutrition? ible beneficiaries under 5 years of age, preg o, infants, and children (WIC). WIC does not provide the desired product, I	acilities' per diem rat iduals with Intellecti parately as a pharm NO YES NO gnant and postpartu Medicaid may autho peeds, Medicaid may to this form.	ate for residents in a long-term care facility (define tual Disabilities (ICF/IID) or psychiatric residentia macy point of sale service. ible tum women must register with the federal progra horize its use. ay authorize additional products. A copy of the	1
Body Weight:	kg orlb. Height:fti			
ENTERAL/CLINICAL				
	Strength:(	Quantity /Month		
	Length of			
	plement is needed:			
NDC #				
Does beneficiary h	ave an inborn error of metabolism? YES			
Consultation with a	Registered Dietician? YES NO			
Date:	Name:			
Calories prescribed	initially verified by	Ph:	Fax:	
Beneficiary ID#: Be	neficiary Full Name:			
			PAGE 2.C	

SUBMISSION AND/OR APPROVAL OF A DRUG PRIOR AUTHORIZATION REQUEST DOES NOT GUARANTEE MEDICAID PAYMENT FOR PHARMACY PRODUCTS OR THE AMOUNT OF PAYMENT. ELIGIBILITY FOR AND PAYMENT OF MEDICAID SERVICES ARE SUBJECT TO ALL TERMS AND CONDITIONS AND LIMITATIONS OF THE MEDICAID PROGRAM.



**Beneficiary ID#:** 

PHARMACY PRIOR AUTHORIZATION FORM

Division of Medicaid Pharmacy Prior Authorization Unit 550 High St., Suite 1000, Jackson, MS 39201

1 1 1

FAX TO: 1-877-537-0720

For Information Call: 1-877-537-0722

Beneficiary Full Name: \_\_\_\_

## MAXIMUM UNIT OVERRIDE Pharmacy Prior Authorization Form 2D

1 1 1

- In accordance with state law, Medicaid provides up to a 31-day supply of medications.
- The maximum daily dose is determined according to the FDA-approved and manufacturer's suggested recommended daily dose.
- Some drugs have assigned monthly quantity limits, as recommended by DOM's Drug Utilization Review Board, and are subject to the Maximum Unit Override. The specific agents with the corresponding quantity limits can be found at <a href="http://www.medicaid.ms.gov/Pharmacy.aspx">http://www.medicaid.ms.gov/Pharmacy.aspx</a>.
- Medicaid may request chart documentation for verification of submitted information.

*Criteria for Maximum Unit Override*: The request for doses higher than the maximum quantity allowed by Medicaid must be submitted for prior approval:

- The request must be substantiated by diagnosis and supporting medical justification.
- Supporting documentation must be available in the patient record.
- Medication will not be approved for non-FDA approved indications.
- 1. Specific diagnosis: \_\_\_\_

2. If dosing is weight-based or body-surface area based:

Beneficiary's Weight: \_\_\_\_\_

Beneficiary's Height: \_\_\_\_\_

3. Detailed description of reason beneficiary needs a greater quantity allowed than quantity limit or dose great than FDA recommends:

PAGE 2.D

SUBMISSION AND/OR APPROVAL OF A DRUG PRIOR AUTHORIZATION REQUEST DOES NOT GUARANTEE MEDICAID PAYMENT FOR PHARMACY PRODUCTS OR THE AMOUNT OF PAYMENT. ELIGIBILITY FOR AND PAYMENT OF MEDICAID SERVICES ARE SUBJECT TO ALL TERMS AND CONDITIONS AND LIMITATIONS OF THE MEDICAID PROGRAM.

P	PHARMACY PRIOR AUTHORIZATION FORM
D	ivision of Medicaid
PI	harmacy Prior Authorization Unit

550 High St., Suite 1000, Jackson, MS 39201

**Beneficiary ID#:** 

MEDICAID

Beneficiary Full Name: \_

FAX TO: 1-877-537-0720

For Information Call:

1-877-537-0722

## Medical Necessity Prior Authorization Form for EPSDT-eligible beneficiaries Form 2E

The Division of Medicaid has established a program of Early and Periodic Screening., Diagnosis, and Treatment (EPSDT), which provides preventive and comprehensive health services for Medicaid-eligible children and youth up to the age twenty-one (21). The service ends on the last day of the beneficiary's twenty-first (21<sup>st</sup>) birthday month. See MS Administrative Code, Title 23, Part 223.

Reasons for prior authorization request may include, but are not limited to:

Request for more than 5 prescription claims per month

Request for more than 2 non-preferred/brand name prescription claims per month

Request for non-preferred medication

Request for a non-covered drug

Notice: Before submitting a PA request, check for options not requiring PA on the current PDL found at <u>http://www.medicaid.ms.gov/Pharmacy.aspx</u>. Medicaid providers are encouraged to use equally efficacious and cost saving **preferred** agents whenever possible.

Requested Medication (Include strength and dosage formulation)	Diagnosis	Preferred Product (Yes/No)	Requested Quantity Per Month
1			
2			
3			
4			
5			

## Additional Medical Justification, including age waiver, if applicable:

PAGE 2.E

SUBMISSION AND/OR APPROVAL OF A DRUG PRIOR AUTHORIZATION REQUEST DOES NOT GUARANTEE MEDICAID PAYMENT FOR PHARMACY PRODUCTS OR THE AMOUNT OF PAYMENT. ELIGIBILITY FOR AND PAYMENT OF MEDICAID SERVICES ARE SUBJECT TO ALL TERMS AND CONDITIONS AND LIMITATIONS OF THE MEDICAID PROGRAM.

MISSISSIPPI DIVISION OF MEDICALD	<b>PHARMACY PRIOR AUTHORIZATION FORM</b> Division of Medicaid Pharmacy Prior Authorization Unit 550 High St., Suite 1000, Jackson, MS 39201	FAX TO: <b>1-877-537-0720</b> For Information Call: 1-877-537-0722
Beneficiary ID#:	Beneficiary Full Name: _	
Preferred Drug	List Exception Pharmacy Prior Authorization Form	Form 2F

Notice: Before submitting a PA request, check for options not requiring PA on the current PDL found at<a href="http://www.medicaid.ms.gov/Pharmacy.aspx">http://www.medicaid.ms.gov/Pharmacy.aspx</a>.Medicaid providers are encouraged to use equally efficacious andcost saving preferred agents whenever possible.

1. Has the patient experienced treatment failure with the preferred products(s)? Yes No

1st Drug	Length of Therapy

Reason for D/C\_\_\_\_\_\_

2ndDrug\_\_\_\_\_Length of Therapy\_\_\_\_\_

Reason for D/C\_\_\_\_

Attach additional documentation of other treatment failures with preferred drugs if necessary. If no previous preferred drug usage, then additional medical justification must be provided.

2. Does the patient have a condition that prevents the use of the preferred products(s)? Yes No

If YES, list	the inte	eraction(s	):
--------------	----------	------------	----

3. Is there a potential drug interaction between another medication and the preferred products(s)?

Yes No If YES, list the interaction(s):\_\_\_\_\_

4. Has the patient experienced intolerable side effects while on the preferred product(s)? Yes No

If YES, list the side effects: \_\_\_\_\_\_

\*MS Division of Medicaid requires that all information requested on this form be completed for consideration of approval.

PAGE 2.F

SUBMISSION AND/OR APPROVAL OF A DRUG PRIOR AUTHORIZATION REQUEST DOES NOT GUARANTEE MEDICAID PAYMENT FOR PHARMACY PRODUCTS OR THE AMOUNT OF PAYMENT. ELIGIBILITY FOR AND PAYMENT OF MEDICAID SERVICES ARE SUBJECT TO ALL TERMS AND CONDITIONS AND LIMITATIONS OF THE MEDICAID PROGRAM.

	PHARMACY PRIOR AUTHORIZATION FORM	FAX TO: 1-877-537-0720		
	Division of Medicaid Pharmacy Prior Authorization Unit	For Information Call:		
MISSISSIPPI DIVISION OF	550 High St., Suite 1000, Jackson, MS 39201	1-877-537-0722		
Beneficiary	ID#: Beneficiary Full Name:			

Sovaldi® INITIAL THERAPY PA Request Form 2G Section 1

MS Division of Medicaid will approve Sovaldi<sup>®</sup> PA requests for members who meet the following guidelines. This is the INITIAL PA form and will cover the first two 14 day fills and a subsequent 28 day fill. The first and second pages list the various regimens and the clinical situations for which they will be considered medically necessary according to Division of Medicaid criteria, as well as the required supporting documentation. The INITIAL PA must be approved prior to the 1<sup>st</sup> dose. The ONGOING THERAPY PA FORM must be completed before the 3<sup>rd</sup> month of therapy starts.

□Genotype	1
	Treatment naïve/relapsed (regardless of HIV co-infection) → Regimen 1
	Prior null or partial response (w/ or w/out a protease inhibitor) $\rightarrow$ Regimen 2
	IFN intolerant*, AND
	<ul> <li>○ Child-Pugh &lt; 6 → Regimen 5</li> </ul>
	IFN-Intolerant* AND
	○ Child-Pugh ≥6 → Regimen 6
	HIV+, prior null or partial response to PEG/RBV PLUS a protease inhibitor → Regimen 2
	HIV+, AND prior PEG/RBV non-response → Regimen 5
	Re-infection of allograft liver after transplant → Regimen 6
□Genotype	2
	Treatment naïve or relapsed, or null responders w/OUT cirrhosis → Regimen 3
	Treatment experienced w/ prior null or partial response WITH cirrhosis $ ightarrow$ Regimen 1
	Treatment naïve or relapsed, or null responders WITH cirrhosis, AND
	<ul> <li>○ IFN-Intolerant* → Regimen 4</li> </ul>
	Re-infection of allograft liver after transplant → Regimen 6
Genotype	3
	Regardless of prior treatment → Regimen 1
	IFN-Intolerant* → Regimen 6
	Re-infection of allograft liver after transplant → Regimen 6
□Genotype	4
	Regardless of prior treatment → Regimen 1
	IFN-Intolerant* → Regimen 6
□Genotype	5 or 6
	Regardless of prior treatment → Regimen 1
	Liver Transplant
	Patient has diagnosis of hepatocellular carcinoma and is awaiting transplant $ ightarrow$ Regimen 7

## PAGE 2.G Section 1

SUBMISSION AND/OR APPROVAL OF A DRUG PRIOR AUTHORIZATION REQUEST DOES NOT GUARANTEE MEDICAID PAYMENT FOR PHARMACY PRODUCTS OR THE AMOUNT OF PAYMENT. ELIGIBILITY FOR AND PAYMENT OF MEDICAID SERVICES ARE SUBJECT TO ALL TERMS AND CONDITIONS AND LIMITATIONS OF THE MEDICAID PROGRAM.





Pharmacy Prior Authorization Unit 550 High St., Suite 1000, Jackson, MS 39201 For Information Call: 1-877-537-0722

**Beneficiary ID#:** 

Beneficiary Full Name: \_\_\_

Sovaldi® INITIAL THERAPY PA Request Form 2G Section 2

## **REGIMENS:**

- 1. 
  Sovaldi 400mg daily w/ weight-based RBV plus weekly PEG/IFN x84 days (12 weeks)
- 2. 🛛 Sovaldi 400mg daily w/ weight-based RBV plus weekly PEG/IFN x84 days (12 weeks), AND
  - An additional 84 days (12 weeks) of PEG/IFN to follow
- 3. Sovaldi 400mg daily w/ weight-based RBV x84 days (12 weeks)
- 4. Sovaldi 400mg daily w/ weight-based RBV x112 days (16 weeks)
- 5. Sovaldi 400mg daily PLUS Olysio 150mg daily w/ or w/out weight-based RBV x84 days (12 weeks)
- 6. Sovaldi 400mg daily w/ weight-based RBV x168 days (24 weeks)
  - If being for re-infection of allograft liver: will require documented recommendations from transplant center and use of weekly PEG/IFN if tolerated
- 7. Sovaldi 400mg daily w/ weight-based RBV (for up to 48 weeks or until liver transplant)
  - Will require documentation of diagnosis and reauthorization every 28 days

## OTHER:

Please provide clinical rationale for choosing a regimen that is beyond those found within the current guidelines, or for selecting any of the above regimens for alternate genotypes/patient populations.

Sovaldi 400mg daily w/\_\_\_

\_\_\_\_\_days ( weeks)\_\_\_\_

х

PAGE 2.G Section 2

SUBMISSION AND/OR APPROVAL OF A DRUG PRIOR AUTHORIZATION REQUEST DOES NOT GUARANTEE MEDICAID PAYMENT FOR PHARMACY PRODUCTS OR THE AMOUNT OF PAYMENT. ELIGIBILITY FOR AND PAYMENT OF MEDICAID SERVICES ARE SUBJECT TO ALL TERMS AND CONDITIONS AND LIMITATIONS OF THE MEDICAID PROGRAM.



For Information Call: 1-877-537-0722

Beneficiary

ID#: Beneficiary Full Name: \_\_\_\_\_

Sovaldi® INITIAL THERAPY PA Request Form 2G Section 3

#### The following documentation must be submitted with initial request for consideration of approval:

Active HCV infection verified by viral load within the last year		HCV Genotype verified by lab
· · · ·		Documentation of counseling regarding
hepatologist, ID specialist or other Hepatitis specialist.		abstinence from alcohol, IV drug use and
Requires consult within the past year with documentation of		education on how to prevent HCV transmission.
recommended regimen		Documentation of abstinence from drugs and
		alcohol for at least 6 months; negative urine drug
		screen required if there is a history of IV drug use.
Patient is not receiving dialysis and has CrCl > 30mL/min		Current medication list that does NOT include:
Verified by lab results including a creatinine level		carbamazepine, phenytoin, Phenobarbital,
within the past 6 months		oxcarbazepine, rifabutin, rifampin, rifapentine, St.
		John's Wort or tipranavir.
For women of childbearing potential (and male patients with f	emale pa	rtners of childbearing potential):
Patient is not pregnant (or a male with a pregnant fer	nale partr	ner) and not planning to become pregnant during
treatment or within 6 months of stopping		
Agreement that partners will use two forms of effective non-hormonal contraception during treatment and for at		
least 6 months after stopping		
Verification that monthly pregnancy tests will be performed throughout treatment		
For IFN-Intolerant* (for use with regimens 4, 5, 6 or Other if ap	plicable):	
Documented life-threatening side effects or p	otential s	side effects (i.e. history of suicidality)
Decompensated cirrhosis (Child-Pugh >6)		
<ul> <li>Or Child-Pugh &gt; 6 if co-infected with</li> </ul>	HIV	
Blood dyscrasias:		
-	hacolino	platelets < 90,000/ul, or baseline Hgb < 10g/dl
<ul> <li>Baseline neutrophil count &lt;1500/μL, baseline platelets &lt;90,000/μL or baseline Hgb &lt;10g/dL</li> </ul>		
Pre-existing unstable or significant cardiac disease (e.g. history of MI or acute coronary syndrome)		
 Other:		
FOR REGIMEN 7: Transplant date:		
Not yet scheduled		

Provider Signature: \_\_\_\_

**\*MUST MATCH PROVIDER LISTED ON PAGE ONE** 

\_Date of Submission: \_\_\_\_\_

PAGE 2.G Section 3

SUBMISSION AND/OR APPROVAL OF A DRUG PRIOR AUTHORIZATION REQUEST DOES NOT GUARANTEE MEDICAID PAYMENT FOR PHARMACY PRODUCTS OR THE AMOUNT OF PAYMENT. ELIGIBILITY FOR AND PAYMENT OF MEDICAID SERVICES ARE SUBJECT TO ALL TERMS AND CONDITIONS AND LIMITATIONS OF THE MEDICAID PROGRAM.



For Information Call:

1-877-537-0722

_
MISSISSIPPI DIVISION OF
MEDICAID
MEDICATD

**Beneficiary ID#:** 

Pharmacy Prior Authorization Unit 550 High St., Suite 1000, Jackson, MS 39201

Beneficiary Full Name: \_\_

Sovaldi® ONGOING THERAPY PA Request Form 2G Section 4

Mississippi Division of Medicaid will approve Sovaldi<sup>®</sup> PA requests for members who meet the following guidelines. The Initial PA must be approved prior to the 1<sup>st</sup> dose. This ONGOING THERAPY PA FORM must be completed for each month of therapy after first 8 weeks (First 8 weeks are covered on Initial Therapy PA Request).

## **REGIMEN BEING USED:**

- 1. Sovaldi 400mg daily w/ weight-based RBV plus weekly PEG x84 days (12 weeks)  $\Box$
- Sovaldi 400mg daily w/ weight-based RBV plus weekly PEG x84 days (12 weeks)
  a. With an additional 84 days (12 weeks) of PEG/RBV to follow □
- 3. Sovaldi 400mg daily w/ weight-based RBV x84 days (12 weeks) □
- 4. Sovaldi 400mg daily w/ weight-based RBV x112 days (16 weeks) □
- 5. Sovaldi 400mg daily PLUS Olysio 150mg daily w/ or w/out weight-based RBV x84 days (12 weeks)
- 6. Sovaldi 400mg daily w/ weight-based RBV x164 days (24 weeks) □
- 7. Sovaldi 400mg daily w/ weight-based RBV (for up to 48 weeks or until liver transplant)  $\Box$

## □ OTHER:

Please provide clinical rationale for choosing a regimen that is beyond those found within the current guidelines, or for selecting any of the above regimens for alternate genotypes/patient populations.

Sovaldi 400mg daily w/_		x	days (	weeks)
-------------------------	--	---	--------	--------

**D** Patient has remained compliant (>85%) on all medications throughout first 2 months of treatment, AND

- Documentation is attached giving evidence of said compliance in the form of:
  - Week-4 Viral Load showing a LOG decrease in HCV viral RNA, OR
  - Chart notes from an office visit documenting an appropriate compliance discussion, OR
  - Other appropriate lab value (with clinical rationale for use):
- **D** Patient is a woman of child-bearing potential
  - o Monthly pregnancy tests have been performed with negative results, AND
  - Patient agrees to continue use of two forms of effective non-hormonal contraception
- **FOR REGIMEN 7:** Transplant date: \_

\*MUST MATCH PROVIDER LISTED ONE PAGE ONE

Not yet scheduled

Provider Signature: \_\_\_

Date of Submission:

## PAGE 2.G Section 4

SUBMISSION AND/OR APPROVAL OF A DRUG PRIOR AUTHORIZATION REQUEST DOES NOT GUARANTEE MEDICAID PAYMENT FOR PHARMACY PRODUCTS OR THE AMOUNT OF PAYMENT. ELIGIBILITY FOR AND PAYMENT OF MEDICAID SERVICES ARE SUBJECT TO ALL TERMS AND CONDITIONS AND LIMITATIONS OF THE MEDICAID PROGRAM.

MISSISSIPPI DIVISION OF MEDICAID Beneficiary ID#:	PHARMACY PRIOR AUTHORIZATION FORM         Division of Medicaid         Pharmacy Prior Authorization Unit         550 High St., Suite 1000, Jackson, MS 39201         Beneficiary Full Name:	FAX TO: 1-877-537-0720 For Information Call: 1-877-537-0722
Synagis Prior Aut	horization Form <sup>*</sup> Form 2H starting October 29, 2013 - March 31, 2014 for a maximum of up to 5 inject	
PHARMACY INFORM following list includ	MATION – Synagis <sup>®</sup> is available through a limited distribution networ les approved pharmacy providers from the 2013-2014 seasons. If the , please select other and provide pharmacy provider information (na	rk established by the manufacturer. The e approved provider for this request is not
Lincare	1EDFUSION (BriovaRx) 🗌 NMMC 🗌 UMC 🗌 VitalCare	
Other NPI:	PH:Fax:	
NDC#:	Gestational Age:Wks.:Days:Birth Weigh	t:lbsoz.
Current Weight:	lbsoz. Date last weighed:	
Did the patient rec	eive Synagis in the hospital? Yes No if yes, list date(s) of	administration:
* MS Division of Me	edicaid requires that all information requested on this form be compl	leted for consideration of approval.
Risk Factors: Check	all that apply.	

Chronic Lung Disease with a diagnosis of BPD requiring medical treatment within the past six months prior to RSV season (e.g. diuretics, systemic steroids, oxygen on continuous basis, bronchodilators or ventilator dependent). Chronic Lung Disease (CLD) also known as bronchopulmonary dysplasia (BPD): an infant less than 32 weeks' gestation evaluated at 36 weeks' postmenstrual age or an infant of more than 32 weeks' gestation evaluated at more than 28 days but less than 56 days of age who has been receiving supplemental oxygen for more than 28 days. CLD of prematurity of is defined as CLD with gestational age less than 35 weeks. High risk is defined as those who receive treatment for CLD within the previous 6 months prior to RSV season, specifically treatment with corticosteroids, diuretics, bronchodilators or oxygen. Note: CLD does not include croup, URI, bronchitis, bronchiolitis, asthma, or wheezing.

Hemodynamically Significant Congenital Heart Disease. (CHD): children with congenital heart disease who are receiving medication to control congestive heart failure, have moderate to severe pulmonary hypertension, or have cyanotic heart disease. Decisions regarding prophylaxis with Synagis in children with CHD should be made on the basis of the degree of the physiologic cardiovascular compromise.

## \*\*\*Supporting documentation must be submitted with request\*\*\*

- Severe neuromuscular disease up to 12 months
- Congenital abnormality of the airway up to 12 months
- Is the child in Day Care?

Does the child have siblings who are permanent resident in the home and less than 5 years old?

Mississippi Medicaid is a federally-subsidized health care program funded with public dollars. As such, I confirm that this medication will be administered to the patient for whom it is dispensed. If I or my staff are unable to administer this medication to the designated patient, I acknowledge that I am responsible for notifying the dispensing pharmacy immediately

PAGE 2.H

SUBMISSION AND/OR APPROVAL OF A DRUG PRIOR AUTHORIZATION REQUEST DOES NOT GUARANTEE MEDICAID PAYMENT FOR PHARMACY PRODUCTS OR THE AMOUNT OF PAYMENT. ELIGIBILITY FOR AND PAYMENT OF MEDICAID SERVICES ARE SUBJECT TO ALL TERMS AND CONDITIONS AND LIMITATIONS OF THE MEDICAID PROGRAM.

1	PHARMACY PRIOR AUTHORIZATION FORM	FAX TO: 1-877-537-0720
Ś	Division of Medicaid Pharmacy Prior Authorization Unit	For Information Call:

550 High St., Suite 1000, Jackson, MS 39201

For Information Call: 1-877-537-0722

**Beneficiary ID#:** 

MEDICAID

ISSISSIPPI DIVIS

Beneficiary Full Name:

#### PHARMACY PRIOR AUTHORIZATION APPEAL/ RECONSIDERATION REQUEST FORM Form 2I

- MS Division of Medicaid requires that all information requested on this form be completed for consideration of approval.
- Request must be submitted within 30 (thirty) days form the date of the denial notice.
- Medicaid beneficiary or prescriber may submit a written request on this form.
- Beneficiary and/or prescriber is encouraged to submit additional information which may affect the appeal review determination.

PA REQUEST INFORMATION:				
Date of Request:	Requested By:	Prescriber	Beneficiary	
Date of Denial Notification:				
RATIONALE/MEDICAL REASON FOR RECONSIDERATION				

PAGE 2.I

SUBMISSION AND/OR APPROVAL OF A DRUG PRIOR AUTHORIZATION REQUEST DOES NOT GUARANTEE MEDICAID PAYMENT FOR PHARMACY PRODUCTS OR THE AMOUNT OF PAYMENT. ELIGIBILITY FOR AND PAYMENT OF MEDICAID SERVICES ARE SUBJECT TO ALL TERMS AND CONDITIONS AND LIMITATIONS OF THE MEDICAID PROGRAM.